← Back to Search

Monoclonal Antibodies

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new medicine called PF-07257876 that targets two proteins on cancer cells. It is for patients with advanced or metastatic tumors who have no other treatment options. The medicine helps the immune system recognize and attack the cancer cells.

Eligible Conditions
  • Ovarian Cancer
  • Squamous Cell Carcinoma
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with adverse events (AEs)
Number of participants with clinically significant laboratory abnormalities
Number of participants with dose limiting toxicities (DLTs) in Dose Escalation (Part 1)
+1 more
Secondary study objectives
Duration of response (DOR)
Immunogenicity of PF-07257876
Intratumor PD-L1 expression
+12 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Dose Expansion (Part 2) - Cohort 2 (SCCHN)Experimental Treatment1 Intervention
Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07257876 at the recommended dose from Part 1.
Group II: Dose Expansion (Part 2) - Cohort 1 (NSCLC)Experimental Treatment1 Intervention
Participants with non-small cell lung cancer (NSCLC) will receive PF-07257876 at the recommended dose from Part 1.
Group III: Dose Escalation (Part 1)Experimental Treatment1 Intervention
Participants will receive PF-07257876 at escalating dose levels.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07257876
2021
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,669 Previous Clinical Trials
17,861,895 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,553 Previous Clinical Trials
14,902,897 Total Patients Enrolled

Media Library

PF-07257876 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04881045 — Phase 1
Non-Small Cell Lung Cancer Research Study Groups: Dose Escalation (Part 1), Dose Expansion (Part 2) - Cohort 2 (SCCHN), Dose Expansion (Part 2) - Cohort 1 (NSCLC)
Non-Small Cell Lung Cancer Clinical Trial 2023: PF-07257876 Highlights & Side Effects. Trial Name: NCT04881045 — Phase 1
PF-07257876 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04881045 — Phase 1
~7 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top